Skip to main content

$0.062 0.002 (3.33%)

High

$0.06

Low

$0.06

Trades

18

Turnover

$32,113

Volume

526,676
30 June 2023 at 3:59pm
Register to track DXB and receive email alerts.
Subject
DXB Ann: Constitution

DXB Ann: Results of Meeting

DXB Ann: Chair address and CEO presentation to AGM

DXB Ann: Investor Briefing

DXB Ann: Letter to Shareholders, Notice of AGM & Proxy Form

DXB Ann: AusBioInvest Presentation, including FSGS recruitment update

DXB Ann: Quarterly Appendix 4C and Activities Report

DXB Ann: Dimerix Receives A$6.0M R&D Tax Incentive Rebate

DXB Ann: Notification of Date of 2022 AGM

DXB Ann: Investor Presentation

DXB Ann: Appendix 4G and Corporate Governance Statement

DXB Ann: Appendix 4E and 2022 Annual Report

DXB Ann: CLARITY 2.0 COVID-19 Study Concludes Recruitment

DXB Ann: Notification of cessation of securities - DXB

DXB Ann: New Patent Family Application for DMX-700

DXB Ann: Quarterly Appendix 4C and Activities Report

DXB Ann: Notification regarding unquoted securities - DXB

DXB Ann: DMX-700 Study Shows Significant 80% Reduction in Lung Injury

DXB Ann: REMAP-CAP COVID-19 Study Analysis Update

DXB Ann: New Clinical Trial for DMX-200 in Diabetic Kidney Disease

DXB Ann: Dimerix to Present at BIO International Convention

DXB Ann: Phase 3 FSGS Kidney Trial First Patient Recruited

DXB Ann: Release of Shares from Voluntary Escrow

DXB Ann: Dimerix presentation at Bioshares Biotech Summit

DXB Ann: FDA IND Approval for Phase 3 Study of DMX-200 in FSGS

DXB Ann: Quarterly Appendix 4C and Activities Report

DXB Ann: Dimerix Receives A$3.7M R&D Tax Incentive Rebate

DXB Ann: Investor Presentation

DXB Ann: Dimerix Investor Call and Presentation

DXB Ann: DSMB Change to REMAP-CAP COVID-19 Study

DXB Ann: Investor Presentation

DXB Ann: Half-Year Financial Report & Appendix 4D - 31 December 2021

DXB Ann: Dimerix Appoints Chief Medical Officer

DXB Ann: First Regulatory Approval in Europe for DMX-200 FSGS Study

DXB Ann: Quarterly Appendix 4C and Activities Report

DXB Ann: Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

DXB Ann: Ethics Approval in Australia for Phase 3 COVID-19 Study

DXB Ann: Dimerix Receives Further MRFF Funding for DMX-200

DXB Ann: DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe

DXB Ann: Pause in Trading

DXB Ann: Notification regarding unquoted securities - DXB

DXB Ann: Investor Presentation

DXB Ann: Quarterly Appendix 4C and Activities Report

DXB Ann: First Approvals Received for Start of Phase 3 FSGS Trial

DXB Ann: Phase 3 DMX-200 COVID-19 Study Expands into Australia

DXB Ann: Change in substantial holding

DXB Ann: Becoming a substantial holder

DXB Ann: Secondary Trading Notice Pursuant to Section 708A(5)(e)

DXB Ann: Change of Director's Interest Notices - JW, HA, SP and NW

DXB Ann: Notification regarding unquoted securities - DXB

Register to track DXB and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX